Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics Inc (NQ: MRSN )

22.99 USD -0.55 (-2.34%)
Official Closing Price Updated: 6:37 PM EST, Dec 3, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 990,700
Open 24.00
Bid (Size) 21.02 (1)
Ask (Size) 23.26 (2)
Prev. Close 23.54
Today's Range 22.41 - 24.32
52wk Range 3.670 - 26.71
Shares Outstanding 22,901,853
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer
From GlobeNewswire News Releases

Performance

YTD
+328.92%
+328.92%
1 Month
+14.44%
+14.44%
3 Month
+35.16%
+35.16%
6 Month
+15.30%
+15.30%
1 Year
+449.34%
+449.34%

More News

Read More
Mersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and Pipeline
From GlobeNewswire News Releases
Mersana Therapeutics to Host Webinar Highlighting Immunosynthen STING-Agonist ADC Platform and Pipeline
From GlobeNewswire News Releases
Mersana Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference
From GlobeNewswire News Releases
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates
From GlobeNewswire News Releases
Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
From GlobeNewswire News Releases
Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study
From GlobeNewswire News Releases
First Week of MRSN January 2021 Options Trading
Tags Stocks
From Market News Video
MRSN Crosses Above Average Analyst Target
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.